Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A compound having Formula 1:



(Formula 1)

and the pharmaceutically-acceptable salts and prodrugs thereof, wherein:

R_1 is pyridyl or pyrimidinyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, C_1-C_6alkylthio, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13} where R_{13} is C_1-C_3haloalkyl, phenyl, heterocycloalkyl, or heteroaryl;

W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

X is N or CH;

R_2 is C_1-C_7alkyl, C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, or (C_1-C_6alkoxy)C_1-C_6alkoxy; or

R_2 is phenyl(C_0-C_2alkyl) or heteroaryl(C_0-C_2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from

(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy,and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, heterocycloalkyl(C_0-C_2alkyl), and –C(O)R_{13}; each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino;

Z_2 is



wherein

R_8 and R_9 are independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, or halogen; and n is 0, 1, or 2;

R_{10} and R_{11} are independently

(iii) hydrogen or C_1-C_6alkyl; or

(iv) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13};

R_3 is hydrogen or C_1-C_6alkyl, or

R_3 is C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6 alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13}; or

R_3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13}.

2. (Original) A compound or salt according to Claim 1, wherein

R_1 is 3- or 4-pyridyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

W is phenyl or a 5- or 6-membered heteroaryl ring; substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

X is N or CH;

R_2 is C_1-C_7alkyl, C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, or (C_1-C_6alkoxy)C_1-C_6alkoxy; or

R_2 is phenyl(C_0-C_2alkyl) or 5- or 6-membered heteroaryl(C_0-C_2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from

(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy, and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and heterocycloalkyl(C_0-C_2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino;

Z_2 is



wherein

R_8 and R_9 are independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, or halogen; and n is 0, 1, or 2;

R_{10} and R_{11} are independently

(iii) hydrogen or C_1-C_6alkyl; or

(iv) phenyl or a 5- or 6 membered heteroaryl ring, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

R_3 is hydrogen or C_1-C_6alkyl, or

R_3 is C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), phenyl, or a 5- or 6-membered heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio,

mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl; or

R_3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl.

3. (Original) A compound or salt according to Claim 2 wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino.

4. (Original) A compound or salt according to Claim 3 wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy.

5. (Previously presented) A compound or salt according to Claim 4 wherein

W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl

6. (Original) A compound or salt according to Claim 5 wherein

W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen

from hydroxy, nitro, cyano, amino, halogen, oxo, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino.

7. (Original) A compound or salt according to Claim 6, wherein W is imidazolyl, pyrrolyl, or pyrazolyl, each of which is substituted with 0 to 2 substituents independently chosen from hydroxy, cyano, halogen, oxo, C_1-C_4alkyl, C_1-C_4alkoxy, trifluoromethyl, and trifluoromethoxy.

8. (Previously presented) A compound or salt according to Claim 4 of Formula 2



(Formula 2).

9. (Previously presented) A compound or salt according to Claim 4 of Formula 3



(Formula 3).

10. (Previously presented) A compound or salt according to Claim 4 of Formula 4



(Formula 4).

11. (Previously presented) A compound or salt according to Claim 9, wherein X is N.

12. (Previously presented) A compound or salt according to Claim 9, wherein X is CH.

13. (Previously presented) A compound or salt according to Claim 7 wherein Z_2 is



wherein

R_8 and R_9 are independently hydrogen or C_1-C_6alkyl; and n is 0, 1, or 2; and

R_{10} and R_{11} are independently hydrogen, C_1-C_6alkyl, or phenyl.

14. (Original) A compound or salt according to Claim 13, wherein Z_2 is



wherein, R_{10} and R_{11} are independently hydrogen, methyl or ethyl.

15. (Original) A compound or salt according to Claim 14 wherein R_{10} and R_{11} are both hydrogen.

16. (Previously presented) A compound or salt according to Claim 15 of Formula 5



(Formula 5).

17. (Previously presented) A compound or salt according to Claim 15 of Formula 6



(Formula 6).

18. (Previously presented) A compound or salt according to Claim 15 wherein R_2 is phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which may be either directly attached or bound via a C_1-C_2alkyl linker, and each of which is substituted with 0 to 3 substituents independently chosen from:

(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy, and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and heterocycloalkyl(C_0-C_2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino.

19. (Original) A compound or salt according to Claim 18, wherein

R_2 is phenyl(C_0-C_2alkyl), pyridyl(C_0-C_2alkyl), or pyrimidinyl(C_0-C_2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from:

(i) hydroxy, halogen, nitro, cyano, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and

(ii) C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, C_1-C_4alkylthio, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), and heterocycloalkyl(C_0-C_2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino.

20. (Original) A compound or salt according to Claim 19, wherein

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

21. (Previously presented) A compound or salt according to Claim 20, wherein

R_3 is hydrogen or C_1-C_6alkyl, or

R_3 is C_3-C_7cycloalkyl, (C_3-C_7cycloalkyl)methyl, heterocycloalkyl, (heterocycloalkyl)C_1-C_2alkyl, phenyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino; or

R_3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino.

22. (Original) A compound or salt according to Claim 21, wherein

R_3 is hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl(C_0-C_1alkyl), phenyl, or phenoxyphenyl.

23. (Original) A compound or salt according to Claim 22, wherein R_3 is hydrogen or C_1-C_4alkyl.

24. (Original) A compound or salt according to Claim 1 of Formula 7



(Formula 7).

25. (Original) A compound or salt according to Claim 1 of Formula 8



(Formula 8).

26. (Original) A compound or salt according to Claim 1 of Formula 9



(Formula 9).

27. (Previously presented) A compound or salt according to Claim 24, wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy;

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and

(ii) C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), piperazinyl(C_0-C_1alkyl), piperidinyl(C_0-C_1alkyl) and morpholinyl(C_0-C_1alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_2alkoxy, and mono- and di-(C_1-C_4alkyl)amino; and

R_3 is hydrogen or C_1-C_4alkyl.

28. (Original) A compound or form thereof according to Claim 1, wherein the compound is:

1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(4-Methoxy-3-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-3-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Chloro-2-methoxy-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Fluoro-2-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Chloro-2-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Chloro-2,4-dimethoxy-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(4-Methyl-3-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(4-Chloro-3-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea; or

1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(3-pyridin-4-yl-pyrazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

29. (Previously presented) A compound or form thereof according to Claim 1, wherein the compound exhibits a IC_{50} of 1 micromolar or less in a standard in *vitro* assay of $EphB_4$ kinase activity.

30. (Previously presented) A compound or form thereof according to Claim 1, wherein the compound exhibits a IC_{50} of 500 nanomolar or less in a standard in *vitro* assay of $EphB_4$ kinase activity.

31. (Previously presented) A compound or form thereof according to Claim 1, wherein the compound exhibits a IC_{50} of 100 nanomolar or less in a standard in *vitro* assay of $EphB_4$ kinase activity.

32. (Previously presented) A pharmaceutical composition, comprising a compound or form thereof according to Claim 1, together with at least one pharmaceutically acceptable carrier or excipient.

33. (Original) A pharmaceutical composition according to Claim 32, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup, ophthalmic solution, or a transdermal patch.

34. (Original) A packaged pharmaceutical composition, comprising

(a) a pharmaceutical composition according to Claim 32 in a container; and

(b) instructions for using the composition to treat a patient suffering from an disease or disorder responsive to kinase activity modulation of one or more tyrosine kinase.

35. (Original) The packaged pharmaceutical composition of Claim 34 wherein the disease or disorder responsive to kinase activity modulation is cancer or a disease characterized by pathological angiogenesis.

36. (Original) The package pharmaceutical composition of Claim 34 wherein the disease characterized by pathological angiogenesis is a cancerous tumor, macular degeneration, or diabetic retinopathy.

37. (Original) A method of reducing medication error and enhancing therapeutic compliance of a patient being treated for a disease or disorder responsive to tyrosine kinase activity modulation, the method comprising providing a packaged pharmaceutical preparation according to Claim 34 wherein the instructions additionally include contraindication and adverse reaction information pertaining to the package pharmaceutical composition.

38. (Previously presented) A method of modulating $EphB_4$ kinase activity, the method comprising contacting cells expressing $EphB_4$ kinase with a compound or form thereof according to Claim 1 in an amount sufficient to detectably inhibit $EphB_4$ kinase activity *in vitro.*

39. (Previously presented) A method of modulating VEGF-R2 activity, the method comprising contacting cells expressing VEGF-R2 with a compound or form thereof according to Claim 1 in an amount sufficient to detectably inhibit VEGF-R2 activity *in vitro.*

40. (Previously presented) A method of modulating c-Kit activity, the method comprising contacting cells expressing c-Kit with a compound or form thereof according to Claim 1 in an amount sufficient to detectably inhibit c-Kit activity *in vitro.*

41. (Previously presented) A method of modulating Tie-2 activity, the method comprising contacting cells expressing Tie-2 with a compound or form thereof according to Claim 1 in an amount sufficient to detectably inhibit Tie-2 activity *in vitro.*

42. (Currently Amended) A method of modulating VEGF-R2, $EphB_4$, Tie-2, and c-Kit activity, the method comprising contacting cells expressing VEGF-R2, $EphB_4$, Tie-2, and c-Kit with a compound according to claim 1 ~~having a molecular weight less than 600 amu~~ in an

amount sufficient to detectably inhibit the activity of at least one of VEGF-R2, $EphB_4$, Tie-2, or c-Kit *in vitro*.

43. (Cancelled)

44. (Cancelled)

45. (Cancelled)

46. (Previously presented) A method of treating a patient having a disease or disorder responsive to kinase activity modulation comprising administering to the patient an effective amount of a compound according to Claim 1.

47. (Previously presented) The method of Claim 46 wherein the patient is a human.

48. (Original) The method of Claim 46 wherein the patient is a cat or dog.

49. (Original) The method of Claim 46 wherein the disease or disorder responsive kinase activity modulation is cancer or a disease characterized by pathological angiogenesis.

50. (Original) The method of Claim 49 wherein the disease characterized by pathological angiogenesis is a cancerous tumor, macular degeneration, or diabetic retinopathy.

51. (Original) The method of Claim 46 wherein the compound or form is administered orally.

52. (Previously presented) A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with a compound or form thereof according to Claim 1 under conditions that permit binding of the compound or form to the angiogenic kinase, detecting a level of the compound or form bound to the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase.

53. (Original) The method of Claim 52 wherein the angiogenic kinase is Tie-2, VEGF-R2, or $EphB_4$.

54. (Original) The method of Claim 53 wherein the compound or form thereof is radiolabelled.

55. (Original) The method of Claim 53, which additionally comprises

separating unbound compound from bound compound; and determining the amount of bound compound in the sample.

56. (Original) The method of claim 42 wherein the cells expressing VEGF-R2, $EphB_4$, Tie-2, and c-Kit with a compound are contacted with the compound having a molecular weight less than 600 amu in an amount sufficient to detectably inhibit the activity of VEGF-R2, $EphB_4$, Tie-2, and c-Kit *in vitro*.

57. (Previously presented) A compound or salt according to Claim 25, wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy;

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and (ii) C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), piperazinyl(C_0-C_1alkyl), piperidinyl(C_0-C_1alkyl) and morpholinyl(C_0-C_1alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_2alkoxy, and mono- and di-(C_1-C_4alkyl)amino; and

R_3 is hydrogen or C_1-C_4alkyl.

58. (Previously presented) A compound or salt according to Claim 26, wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy;

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and (ii) C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), piperazinyl(C_0-C_1alkyl), piperidinyl(C_0-C_1alkyl) and morpholinyl(C_0-C_1alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_2alkoxy, and mono- and di-(C_1-C_4alkyl)amino; and

R_3 is hydrogen or C_1-C_4alkyl.